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Abstract
To rapidly detect rifampin, isoniazid and multidrug resistance in Mycobacterium tuberculosis isolates, a new system (BluePoint MtbDR, Bio
Concept Inc., Taichung, Taiwan) including an oligonucleotide array and an automatic reader was evaluated. The array simultaneously
identiﬁes M. tuberculosis and predominant mutations in the rpoB, katG and inhA upstream regulatory region (inhA-r) genes. The system was
assessed with 324 clinical M. tuberculosis isolates, including 210 multidrug-resistant, 41 rifampin mono-resistant, 34 isoniazid mono-resistant
and 39 fully susceptible isolates. The results were compared with those obtained using the GenoType MTBDRplus test, drug-resistant gene
sequencing and conventional drug susceptibility testing. The detection limit of the array was 25 pg DNA. The array and the GenoType
MTBDRplus test detected 179 (85.2%) and 182 (86.7%) multidrug-resistant M. tuberculosis strains, respectively. The sensitivities of the array
for detecting rifampin and isoniazid resistance were 98.4% and 87.7%, respectively, whereas the sensitivities of the GenoType MTBDRplus
test for detecting rifampin and isoniazid resistance were 98.8% and 88.9%, respectively. No signiﬁcant difference was found between the
tests with respect to their sensitivities to detect multidrug resistance (p 0.66), rifampin resistance (p 0.69) or isoniazid resistance (p 0.68).
The discrepancies were mainly attributed to rare mutations in inhA-r, which were not included in the array. The array can directly reveal
transmission-associated mutations, which are useful for epidemiological investigations. The turnaround time of the array test was 6–7 h.
This study conﬁrms the feasibility of using this system for rapid and accurate diagnosis of isoniazid and rifampin resistance in M. tuberculosis.
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Introduction
The emergence of drug-resistant tuberculosis, particularly
multidrug-resistant tuberculosis (MDR-TB), which is deﬁned as
a Mycobacterium tuberculosis complex isolate resistant to at
least isoniazid and rifampin, is a public health concern and
threatens global TB control programmes. In late 2012, the
WHO estimated that, globally, 3.7% (2.1–5.2%) of new cases
and 20% (13–26%) of previously treated cases involve MDR-TB
[1]. The conventional culture-based drug susceptibility testing
(DST) usually requires 2–4 weeks to complete. Hence, new
diagnostics can have a great impact on early diagnosis and
prompt management of MDR-TB.
Based on mutations in the rpoB gene conferring rifampin
resistance and mutations in the katG gene and in the upstream
regulatory region of the inhA (inhA-r) gene conferring isoniazid
resistance in M. tuberculosis, rapid detection methods for drug
resistance were developed. In 2009, the WHO recommended
a line-probe assay, the GenoType MTBDRplus test (Hain
Lifescience GmbH, Nehren, Germany), which can identify the
M. tuberculosis complex and detect resistance to rifampin and
isoniazid. The performance of the GenoType MTBDRplus test
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for detecting rifampin and isoniazid resistance has been well
documented [2–8].
Microarray analysis of M. tuberculosis has facilitated a range
of additional studies to provide important contributions on
its mechanisms of drug resistance, host–pathogen interac-
tions, in vitro and in vivo gene expression and functional
analysis of particular genes [9]. Previously, several in-house
or commercial arrays were designed for differentiating the
M. tuberculosis complex from non-tuberculous mycobacteria
[10,11] and for rapid detection of MDR and mono-drug-resis-
tant M. tuberculosis as well as M. tuberculosis that is resistant
to second-line anti-TB drugs [12–19]. The TB-Biochip
oligonucleotide microarray system (Engelhardt Institute of
Molecular Biology, Moscow, Russia), evaluated by Caoili et al.
[13], displayed 80% sensitivity for rifampin resistance and
90.7% accuracy for clinical isolates. Similarly, a short-oligo-
nucleotide-ligation DNA chip (SOLAC) demonstrated 87.3%
sensitivity in detecting rifampin resistance [14]. Another
microarray-based method for pncA genotyping of pyrazina-
mide resistance was shown to be a valuable tool for the rapid
identiﬁcation of potential pyrazinamide-resistant M. tuberculo-
sis isolates [15]. Another low cost and density microarray
showed 93.8%, 97.5% and 56.2% concordance in detecting
rifampin resistance, isoniazid resistance and MDR-TB,
respectively [12].
A new nylon membrane array (BluePoint MtbDR, Bio
Concept Inc., Taichung, Taiwan) was recently developed to
simultaneously identify the M. tuberculosis complex and deter-
mine its resistance to rifampin and isoniazid. The array can
detect mutations in six codons in the hot-spot region of the
rpoB gene, codon 315 of the katG gene and the upstream
regulatory region (nucleotide positions 8 and 15) of the
inhA-r gene (Fig. 1). Here, we report the performance of the
array and the GenoType MTBDRplus test for routine clinical
practice using a culture-based phenotypic DST as a gold
standard.
Materials and Methods
Mycobacterium tuberculosis isolates
Mycobacterium tuberculosis isolates were collected from hospi-
tals throughout Taiwan in 2007–2012. In this study, 324
isolates were evaluated, including 210 MDR, 41 rifampin
mono-resistant, 34 isoniazid mono-resistant and 39 fully
susceptible isolates.
Drug susceptibility testing
The agar proportion method was performed with Middlebrook
7H10 (Creative Microbiologicals, Taipei, Taiwan). The critical
drug concentrations were 0.2 lg/mL and 1.0 lg/mL for isoni-
azid and 1.0 lg/mL for rifampin. Growth on the control medium
was compared with the growth on the drug-containing medium
to determine susceptibility. The DST results were categorized
as resistant or susceptible. The tests were validated by
determining the susceptibility of M. tuberculosis H37Rv.
Molecular methods
DNA was prepared according to the protocol provided by the
manufacturer of the GenoType MTBDRplus kit and used for
the array and DNA sequencing. The genotypic assays were
evaluated blindly by two medical technologists in parallel. The
array hybridization procedures consisted of ampliﬁcation of
the regions containing the rpoB, katG and inhA-r genes by
multiplex PCR. Hybridized spots were read on a reader
supplied by the kit manufacturer. The protocol used for array
hybridization was as follows: 20 mL of 0.5 9 sodium chloride
sodium citrate (SSC) wash buffer was added to a 9-cm Petri
FIG. 1. Layout of probes on the array (a) position marker, (b) positive control, (c) internal ampliﬁcation control and (d) wild-type probe.
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dish containing the arrays for 10 min, and the wash buffer was
subsequently discarded. The arrays were then placed into a
24-well cell culture plate, and 300 lL of hybridization buffer
was added into each well. The digoxigenin-labelled PCR
products obtained by multiplex PCR were denatured at
99°C for 5 min and cooled on ice for 5 min. Hybridization
was performed by adding 20 lL of digoxigenin-labelled PCR
products into the well and incubating for 1 h at 50°C with
gentle shaking. After hybridization, the following steps were
performed at room temperature. The arrays were washed
twice with 20 mL of 0.25 9 SSC wash buffer for 2 min and
were incubated with 20 mL of 1 9 blocking reagent contain-
ing 8 lL of anti-digoxigenin antibodies for 30 min with shaking.
The antibody solution was removed, and the arrays were
subjected to sequential 5-min incubations with 20 mL of maleic
acid buffer and 20 mL of detection buffer. Colour develop-
ment was achieved by incubation with 50 lL of substrate
(nitro-blue tetrazolium choride/5-bromo-4-chloro-30-indoly-
phosphate p-toluidine salt) (diluted 50-fold with detection
buffer) for 15 min in the dark. After colour development, the
arrays were washed twice (5 min each time) with pure water
and dried in a 60°C oven. A drug-resistant isolate was
identiﬁed when the hybridization signal of a mutant probe on
the array was stronger than that of the corresponding
wild-type probe. The GenoType MTBDRplus test was per-
formed, and the results were read according to the manufac-
turer’s instructions.
Determination of detection limit of the array
Mycobacterium tuberculosis H37Rv was used to determine the
detection limit of the array. The DNA of the strain was serially
diluted ten-fold (1 ng/lL to 1 fg/lL) with a carrier DNA
(polyadenylic acid; Sigma-Aldrich, St Louis, MO, USA; 1 lg/mL
in PBS). The diluted DNA (2.5 lL) was used for PCR followed
by hybridization to the array. In addition, one MDR M. tuber-
culosis strain and the M. tuberculosis H37Rv strain were used
for determining heteroresistance. Different ratios of bacilli
(1000 : 1, 100 : 1, 10 : 1 and 1 : 1) of the two strains were
prepared for assessment.
Sequencing of the rpoB, katG and inhA-r genes
DNA sequencing was used to resolve the discrepancies
between the current array and the GenoType MTBDRplus
test. The rpoB, katG and inhA-r genes were ampliﬁed by PCR,
and the ampliﬁed regions were sequenced as previously
described to detect mutations [4].
Data analysis
The sensitivity, speciﬁcity, positive predictive value, negative
predictive value and accuracy of the two molecular assays
were calculated. The sensitivities of both assays were
compared using the binomial test. Statistical signiﬁcance was
evaluated by two-tailed Fisher’s exact test, and p <0.05 was
considered statistically signiﬁcant.
Results
Genetic characteristics of study isolates
The DST results for isoniazid and rifampin resistance of the
324 M. tuberculosis isolates are listed in Table 1. All 39 fully
drug-susceptible M. tuberculosis isolates demonstrated wild--
type sequences, as determined by both molecular assays. The
frequencies of mutations detected by the array are listed in
Table 2.
Detection limit of the array
The detection limit of the array was 25 pg DNA. Additionally,
heteroresistance could be detected by the array when the
ratio of resistant to susceptible M. tuberculosis bacilli was
>10 : 1.
The array and the GenoType MTBDRplus test for detection
of rifampin resistance
Of the 41 rifampin mono-resistant and 210 MDR M. tubercu-
losis isolates determined by conventional DST, 41 (100%) and
206 (98.1%), respectively, had mutations conferring rifampin
resistance based on the array results (Table 1). Nevertheless,
41 (100%) and 207 (98.6%) isolates, respectively, contained
Array
GenoType
MTBDRplus
test
No. (%) with the given result as determined by conventional DST
RIF
mono-
resistant
INH
mono-
resistant
All
susceptible
MDR isolatesa
RIF
resistant
INH
resistant MDR
Resistant Resistant 41 (100) 32 (94.1) 0 (0) 206 (98.1) 182 (86.7) 179 (85.2)
Resistant Susceptible 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Susceptible Resistant 0 (0) 1 (2.9) 0 (0) 1 (0.5) 2 (0.9) 3 (1.4)
Susceptible Susceptible 0 (0) 1 (2.9) 39 (100) 3 (1.4) 26 (12.4) 28 (13.3)
DST, drug susceptibility test; INH, isoniazid; MDR, multidrug resistance; RIF, rifampin.
aThe two molecular assays were not signiﬁcantly different with respect to their ability to detect rifampin resistance
(p 0.69), isoniazid resistance (p 0.68) and MDR (p 0.66) in the MDR isolates.
TABLE 1. Drug resistance in 324
Mycobacterium tuberculosis isolates
detected using the array and the
GenoType MTBDRplus assay
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mutations conferring rifampin resistance based on the Geno-
Type MTBDRplus test results. Based on DNA sequencing, all
rifampin mono-resistant isolates had mutations within the
hot-spot region between codons 507 and 533 of the rpoB gene.
The predominant mutations in the rpoB gene detected using
the array were S531L (46.5%), D516V (6.5%), H526Y (6.5%)
and L533P (6.1%) (Table 2). Dual mutations in the rpoB gene
were observed in seven (2.8%) strains based on the array.
Three strains harbouring the L511P mutation also had D516Y,
H526N and H526Q mutations, two strains had the D516Y and
S531L mutations, and two strains had the H526N and L533P
mutations. The sensitivities of the array and the GenoType
MTBDRplus test for detecting rifampin resistance among
M. tuberculosis strains were 98.4% and 98.8%, respectively.
The respective speciﬁcity, positive predictive value, negative
predictive value and accuracy of the array were 100%, 100%,
94.8% and 98.8%; with the GenoType MTBDRplus test, these
values were 100%, 100%, 96.1% and 99.1%, respectively. There
was no signiﬁcant difference between the array and the
GenoType MTBDRplus test with respect to their sensitivities
to detect rifampin (p 0.69) resistance.
The array and the GenoType MTBDRplus test for detection
of isoniazid resistance
Of the 34 isoniazid mono-resistant and 210 MDR M. tubercu-
losis isolates, 32 (94.1%) and 182 (86.7%), respectively, were
found to contain mutations conferring isoniazid resistance
using the array (Table 1), whereas 33 (97.1%) and 184 (87.6%)
isolates, respectively, had mutations conferring isoniazid
resistance based on the GenoType MTBDRplus test. Mutations
conferring either rifampin or isoniazid resistance among
324 M. tuberculosis isolates using the array are listed in
Table 2. The predominant mutations detected in the katG
gene were S315T1 (AGC to ACC mutation) (51%) and S315N
(11.6%), and the predominant mutation in inhA-r was C-15T
(32.6%) (Table 2). Dual mutations were identiﬁed in 15 (7%)
strains using the array; 11 (73.3%) strains had concurrent
S315T1 and C-15T mutations, one strain had concurrent
S315T1 and T-8A mutations, one strain had concurrent
S315T1 and T-8C mutations, and two strains had concurrent
S315N and C-15T mutations in katG and inhA-r. The sensitivity
for detecting isoniazid resistance among M. tuberculosis strains
was 87.7% using the array and 88.9% using the Genotype
MTBDRplus test. The speciﬁcity, positive predictive value,
negative predictive value and accuracy of the array were 100%,
100%, 72.7% and 90.7%, respectively; these values were 100%,
100%, 74.8% and 91.7%, respectively, for the Genotype
MTBDRplus test. The sensitivities of the array and the
Genotype MTBDRplus test for detecting isoniazid resistance
were not signiﬁcantly different (p 0.68).
The array and the GenoType MTBDRplus test for detection
of multidrug resistance
In this study, 179 (85.2%) and 182 (86.7%) MDR M. tuberculosis
isolates were detected using the array and the GenoType
MTBDRplus assay, respectively (Table 1). Of the 179 MDR
isolates detected by the array, the major paired mutations
were rpoB S531L paired with katG S315T1 (16.8%), inhA-r
C-15T (11.7%), katG S315N (6.1%) and inhA-r T-8C (5%).
Whereas katG S315T1 was the major mutation found to pair
with the rpoB S531L (16.8%), D516V (4.5%), H526Y (2.8%) and
L533P (2.8%) mutations. At least ﬁve MDR isolates harboured
the same proﬁles of mutations and are listed in Table 3. The
sensitivities of the array and the GenoType MTBDRplus test
for detecting MDR M. tuberculosis were not signiﬁcantly
different (p 0.66).
Analysis of discordant results
Three M. tuberculosis isolates that were determined to be
MDR by the Genotype MTBDRplus test were identiﬁed as
isoniazid mono-resistant (one isolate) and rifampin
mono-resistant (two isolates) using the array (Fig. 2a–c). Gene
TABLE 2. Gene mutations in Mycobacterium tuberculosis
isolates. Among 324 M. tuberculosis isolates, gene mutations
were detected in 247 rifampin-resistant and 214 isonia-
zid-resistant isolates using the array
Gene mutation or codon analysed No. (%) of isolates
rpoB
L511P 8 (3.2)
Q513K 7 (2.8)
Q513P 3 (1.2)
Q513L 2 (0.8)
D516V 16 (6.5)
D516Y 5 (2.0)
D516F 7 (2.8)
S522L 5 (2.0)
H526Y 16 (6.5)
H526D 14 (5.7)
H526R 9 (3.6)
H526N 6 (2.4)
H526L 1 (0.4)
S531L 113 (45.7)
S531W 6 (2.4)
L533P 13 (5.3)
L511P, D516Y 1 (0.4)
L511P, H526N 1 (0.4)
L511P, H526Q 1 (0.4)
D516Y, S531L 2 (0.8)
H526N, L533P 2 (0.8)
katG
S315T1a 96 (44.9)
S315N 23 (10.7)
S315T2b 5 (2.3)
S315R 1 (0.5)
S315I 1 (0.5)
inhA-r
C-15T 57 (26.6)
T-8C 11 (5.1)
T-8A 3 (1.4)
katG and inhA-r
S315T1, C-15T 11 (5.1)
S315T1, T-8A 1 (0.5)
S315T1, T-8C 1 (0.5)
S315N, C-15T 2 (0.9)
aS315T1, AGC/ACC.
bS315T2, AGC/ACA.
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sequencing was used to resolve the discrepancies between
these results. The sequencing data revealed that the rpoB
D516Y mutation was missed in one MDR isolate by the array
(Fig. 2a). For the two MDR isolates identiﬁed as rifampin
mono-resistant by the array (Fig. 2b,c), one harboured an
inhA-r wild-type deletion (Fig. 2b) and another showed a mixed
pattern of wild-type and mutant katG and inhA-r genes (Fig. 2c)
based on the GenoType MTBDRplus test. Sequencing data
revealed an inhA-r G-17T mutation (Fig. 2b) and a katG R463L
mutation (Fig. 2c). Another isoniazid mono-resistant isolate
determined as susceptible by the array was found to harbour
the inhA-r G-17T mutation (Fig. 2d). Furthermore, of the 28
MDR M. tuberculosis strains, 25 strains were rifampin
mono-resistant using both of the tests. Of the 25 rifampin
mono-resistant strains, sequencing results revealed that one
strain harboured a katGW321S mutation, 11 strains had a katG
R463L mutation (a phylogenetic marker) and 13 strains
showed wild-type in the katG gene. While, in the other three
phenotypic MDR strains, including two rifampin-susceptible/
isoniazid-resistant strains and one rifampin-susceptible/isonia-
zid-susceptible strain using both of the tests, we only found
one strain with an rpoB V176F mutation.
Discussion
To respond to the need for a rapid and accurate diagnostic test
for detecting MDR-TB, we evaluated a specialized oligonucleo-
tide array consisting of eight wild-type and 17 mutant rpoB
probes for detecting rifampin resistance in addition to one
wild-type and ﬁve mutant katG probes and two wild-type and
three mutant inhA-r probes for detecting isoniazid resistance.
The array was compared with the WHO-recommended
GenoType MTBDRplus test, which is useful due to its high
accuracy and speciﬁcity. Previous studies have demonstrated
that the GenoType MTBDRplus test showed outstanding
performance, with 91.7–100% accuracy for detecting rifampin
resistance, 34.6–94.6% accuracy for detecting isoniazid resis-
tance and 78.5–100% accuracy for detecting MDR [2–8]. In this
study, our array identiﬁed 98.4% rifampin-resistant isolates,
87.7% isoniazid-resistant isolates and 85.2% MDR isolates. The
two assays were not signiﬁcantly different with respect to their
ability to detect resistance to rifampin (p 0.69), isoniazid
(p 0.68) or MDR (p 0.66). Overall, the array was comparable
to the GenoType MTBDRplus test with respect to its ability to
detect isoniazid and rifampin resistance. However, due to the
existence of rare mutations outside the hot-spot region or
other less frequently identiﬁed mutations that cause drug
resistance, both molecular assays might still need to be
performed with gene sequencing as an add-on assay.
We found limitations that could hamper the application of
the GenoType MTBDRplus test in routine clinical diagnosis. The
banding patterns of the line-probe assay are not always obvious,
a well-trained medical technician is needed to interpret the test
results even though a commercial scanner has been developed.
Certain mutations, such as rpoB H526Q, do not have a
corresponding probe, so a mutant harbouring this mutation
cannot be clearly identiﬁed by its corresponding amino acid
changes using the GenoType MTBDRplus test because signals of
both wild-type and mutant probes are absent. On the contrary,
the current array can identify exact nucleotide substitutions in
the mutated codon(s), which is useful for epidemiological
investigations. The array has the advantage of low cost and its
hybridization patterns can be clearly interpreted.
Two slide-based chip/array systems are commercially avail-
able for detecting drug-resistant M. tuberculosis. The Combi-
chip Mycobacteria chip (GeneIn Co., Busan, Korea) is an
oligonucleotide chip consisting of seven wild-type and 13
mutant probes for detecting rifampin resistance and two
wild-type and three mutant probes for isoniazid resistance.
The sensitivity of this chip for rifampin resistance determina-
tion is 93%, whereas that for isoniazid resistance determina-
tion is only 71% [20,21]. In addition, the commercially available
CapitalBio DNA microarray (CapitalBio Corp., Beijing, China)
contains even fewer oligonucleotide probes (13 rpoB mutation
probes, two katG gene probes and one inhA regulatory region
mutation probe); the microarray has 93.8% and 76.2%
sensitivity for rifampin and isoniazid susceptibility determina-
tion compared with phenotypic DST [22–24]. Apparently, our
array consists of more comprehensive mutant probes (three
probes for codon 513, three probes for codon 516, six probes
for codon 526 and two probes for codon 531 for the
determination of rifampin resistance; and ﬁve probes for
codon 315 and three probes for inhA-r for the determination of
isoniazid resistance) and complementary wild-type probes
compared with similar systems. Consequently, the array in this
TABLE 3. Distribution of gene mutations among 179 multi-
drug-resistantMycobacterium tuberculosis isolates detected by
the array
Gene and mutation
No. (%) of isolatesarpoB katG inhA-r
S531L S315T1 30 (16.8)
S531L C-15T 21 (11.7)
S531L S315N 11 (6.1)
S531L T-8C 9 (5.0)
D516V S315T1 8 (4.5)
S531L S315T1 C-15T 6 (3.4)
H526Y S315T1 5 (2.8)
L533P S315T1 5 (2.8)
aOut of 84 (46.9%) isolates, fewer than ﬁve strains harboured the same proﬁles of
mutation.
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(a)
(b)
(c)
(d)
FIG. 2. The array and the GenoType MTBDRplus test yielded different results in some cases. Three multidrug-resistant Mycobacterium tuberculosis
isolates (a–c) and one isoniazid (INH) mono-resistant isolate (d) were analysed with the array and the GenoType MTBDRplus test, and discrepant
results were obtained. RIF, rifampin.
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study was better able to detect rifampin resistance (p <0.01)
and isoniazid resistance (p <0.05) compared with the Capital-
Bio DNA microarray.
In our study, H526N was found in 3.6% (9/247) of the
rifampin-resistant isolates, and the corresponding probe was
not included in the CapitalBio DNA microarray. Furthermore,
although the C-15T mutation in inhA-r was predominant, we
identiﬁed T-8C and T-8A mutations in 7.5% (16/214) of the
isoniazid-resistant isolates. Because mutations in codons 531
and 526 of the rpoB gene and nucleotide –8 of the inhA-r gene
are the most frequently reported mutations in most studies, an
array should include probes for all possible mutations to
increase sensitivity and accuracy. For example, a probe for the
detection of the inhA-r G-17T mutation can be included in the
array described in this study. Geographic differences in
mutation frequencies should also be considered. In this study,
one isoniazid-resistant strain (Fig. 1c) was detected by the
GenoType MTBDRplus test but not by the array. This result
might be a result of (i) heteroresistance of the isoniazid strain,
with the resistance ratio being below the detection limit of the
array or (ii) use of a different polymerase in the PCR, which
could contribute signiﬁcantly to the ampliﬁcation efﬁciency of
templates with increased GC content (>56%) or longer
amplicons (>900 bp) [25].
It is known that rifampin and isoniazid resistance-associated
genes are associated with cross-resistance to other anti-TB
drugs, TB transmission and treatment outcome [26]. For
example,M. tuberculosis isolates that are resistant to a low level
(0.2 mg/L) of isoniazid and susceptible to a high level (1 mg/L) of
isoniazid are usually resistant to ethionamide. Speciﬁc muta-
tions in the katG gene cause a very high level of isoniazid
resistance, whereas mutations in the inhA regulatory region,
particularly C-15T, and inhA structural region, speciﬁcally S94A
and I194T, have been reported to be associated with high-level
resistance to both isoniazid and ethionamide in Latin American-
Mediterranean family MDRM. tuberculosis strains in Lisbon [27].
In this study, 31.8% (57/179) of MDR M. tuberculosis strains
harboured the inhA-r C-15T mutation, signalling the possibility
of high-level concurrent resistance to ethionamide and might be
useful to guide the prescription of other efﬁcacious second-line
regimens. Therefore, the array can be adopted as a rapid
detection test for MDR-TB, and it could be used to suggest the
inclusion of ethionamide in the regimen when no mutation in
the inhA-r C-15T was observed. In addition, mutations in the
rpoB gene could result in cross-resistance to all three rifamycins,
including rifampin, rifabutin and rifapentine. Mycobacterium
tuberculosis isolates with mutations in rpoB codons 143, 511,
516 and 522 and certain mutations in rpoB codons 526 and 529
are susceptible to rifabutin [28]. Therefore, the array evaluated
here can be used to rapidly predict rifabutin susceptibility based
on the presence of H526N and H526L mutations without the
need to wait 2–4 weeks to obtain conventional DST results.
Because the array can detect mutations conferring low-level
rifampin resistance, it can be used to determine more effective
treatment options, leading to more favourable outcomes.
Furthermore, the katG 315 mutation is more likely to confer
additional drug resistance and has less ﬁtness cost [29]. The
impact of the katG 315 mutation on TB transmission was
revealed to be associated with the main lineage of M. tubercu-
losis [30]. Therefore, the current array can also be used for the
preliminary investigation and identiﬁcation of epidemiologically
unlinked cases.
In conclusion, a relatively low-cost oligonucleotide array is
applicable for rapid detection of rifampin and isoniazid
resistance. The accuracy of the test for the detection of
rifampin and isoniazid resistance was found to be comparable
to that of the GenoType MTBDRplus test and the conventional
culture-based DST. Furthermore, the array can be modiﬁed to
include new alleles of isoniazid-resistant genes to improve the
sensitivity for detecting genetically diverse M. tuberculosis
isolates.
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